{
    "id": "correct_subsidiary_00122_0",
    "rank": 47,
    "data": {
        "url": "https://www.slideshare.net/slideshow/09232015-1-mergent-incjohnson-johnson-general-cdocx/253931262",
        "read_more_link": "",
        "language": "en",
        "title": "09232015 1 Mergent, Inc.Johnson & Johnson General C.docx",
        "top_image": "https://cdn.slidesharecdn.com/ss_thumbnails/092320151mergentinc-221101053738-eaaf5972-thumbnail.jpg?width=640&height=640&fit=bounds",
        "meta_img": "https://cdn.slidesharecdn.com/ss_thumbnails/092320151mergentinc-221101053738-eaaf5972-thumbnail.jpg?width=640&height=640&fit=bounds",
        "images": [
            "https://public.slidesharecdn.com/images/next/logo-slideshare-scribd-company.svg?w=128&q=75 1x, https://public.slidesharecdn.com/images/next/logo-slideshare-scribd-company.svg?w=256&q=75 2x",
            "https://image.slidesharecdn.com/092320151mergentinc-221101053738-eaaf5972/85/09232015-1-Mergent-Inc-Johnson-Johnson-General-C-docx-1-320.jpg 320w, https://image.slidesharecdn.com/092320151mergentinc-221101053738-eaaf5972/85/09232015-1-Mergent-Inc-Johnson-Johnson-General-C-docx-1-638.jpg 638w, https://image.slidesharecdn.com/092320151mergentinc-221101053738-eaaf5972/75/09232015-1-Mergent-Inc-Johnson-Johnson-General-C-docx-1-2048.jpg 2048w"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2022-11-01T05:37:37+00:00",
        "summary": "",
        "meta_description": "09232015 1 Mergent, Inc.Johnson & Johnson  General C.docx - Download as a PDF or view online for free",
        "meta_lang": "en",
        "meta_favicon": "https://public.slidesharecdn.com/_next/static/media/favicon.7bc3d920.ico",
        "meta_site_name": "SlideShare",
        "canonical_link": "https://www.slideshare.net/slideshow/09232015-1-mergent-incjohnson-johnson-general-cdocx/253931262",
        "text": "1. 09/23/2015 1 Mergent, Inc. Johnson & Johnson General Company Information Principal Office One Johnson & Johnson Plaza New Brunswick, NJ 08933 USA Phone 732 524-0400 Fax 732 214-0332 Auditor PricewaterhouseCoopers LLP Number of Employees 126,500 (Approximate Full-Time as of 12/31/2014) Country of Incorporation United States Exchange And Ticker NYS : JNJ Primary SIC 2834 : Pharmaceutical preparations Company Website www.jnj.com\n\n2. Primary NAICS 325412 : Pharmaceutical Preparation Manufacturing Closing Stock Price 93.24 (as of 09/22/2015) Incorporated November 1887 , NJ, United States Mergent Dividend Achiever Yes, # of Years: 46 Number of Shareholders 162,062 (record) (as of 02/17/2015) Business Summary Johnson & Johnson is a holding company. Through its subsidiaries, Co. is organized into three segments. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopaedic, surgical care, specialty surgery, cardiovascular care, diagnostics, diabetes care, and vision care markets, which are distributed to wholesalers, hospitals and retailers. Johnson & Johnson 09/23/2015 2 Mergent, Inc.\n\n3. Pricing Information Closing Price As of 09/22/2015 : 93.24 Dividend Yield 3.1103 Earning Per Share(TTM) 5.78 Dividend Per Share(TTM) 2.9 Market Cap(mil) 258,191 52 Week Range 90.73 - 109.07 PE Ratio 16.3866 % Price Change (100 Days) -4.36 09/23/2015 1 Mergent, Inc. Johnson & Johnson General Company Information\n\n4. Principal Office One Johnson & Johnson Plaza New Brunswick, NJ 08933 USA Phone 732 524-0400 Fax 732 214-0332 Auditor PricewaterhouseCoopers LLP Number of Employees 126,500 (Approximate Full-Time as of 12/31/2014) Country of Incorporation United States Exchange And Ticker NYS : JNJ Primary SIC 2834 : Pharmaceutical preparations Company Website www.jnj.com Primary NAICS 325412 : Pharmaceutical Preparation Manufacturing Closing Stock Price 93.24 (as of 09/22/2015) Incorporated November 1887 , NJ, United States Mergent Dividend Achiever Yes, # of Years: 46\n\n5. Number of Shareholders 162,062 (record) (as of 02/17/2015) Business Summary Johnson & Johnson is a holding company. Through its subsidiaries, Co. is organized into three segments. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopaedic, surgical care, specialty surgery, cardiovascular care, diagnostics, diabetes care, and vision care markets, which are distributed to wholesalers, hospitals and retailers. Johnson & Johnson 09/23/2015 2 Mergent, Inc. Pricing Information Closing Price As of 09/22/2015 : 93.24 Dividend Yield 3.1103 Earning Per Share(TTM)\n\n6. 5.78 Dividend Per Share(TTM) 2.9 Market Cap(mil) 258,191 52 Week Range 90.73 - 109.07 PE Ratio 16.3866 % Price Change (100 Days) -4.36 09/23/2015 1 Mergent, Inc. Johnson & Johnson General Company Information Principal Office One Johnson & Johnson Plaza New Brunswick, NJ 08933 USA Phone 732 524-0400 Fax 732 214-0332 Auditor\n\n7. PricewaterhouseCoopers LLP Number of Employees 126,500 (Approximate Full-Time as of 12/31/2014) Country of Incorporation United States Exchange And Ticker NYS : JNJ Primary SIC 2834 : Pharmaceutical preparations Company Website www.jnj.com Primary NAICS 325412 : Pharmaceutical Preparation Manufacturing Closing Stock Price 93.24 (as of 09/22/2015) Incorporated November 1887 , NJ, United States Mergent Dividend Achiever Yes, # of Years: 46 Number of Shareholders 162,062 (record) (as of 02/17/2015) Business Summary Johnson & Johnson is a holding company. Through its subsidiaries, Co. is organized into three segments. The Consumer segment includes a range of products used in the baby care, oral care, skin care,\n\n8. over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopaedic, surgical care, specialty surgery, cardiovascular care, diagnostics, diabetes care, and vision care markets, which are distributed to wholesalers, hospitals and retailers. Johnson & Johnson 09/23/2015 2 Mergent, Inc. Executives Officers Alex Gorsky Title : Chairman Tenure : 27 Age : 55 Total Compensation : $61,989,306 %Change : 2.67 Education : - Dominic J. Caruso Title : Vice President Tenure : 16 Age : 57 Total Compensation : $10,349,033 %Change : 0.26 Education : - Peter M. Fasolo Title : Vice President Tenure : 5 Age : 52\n\n9. Total Compensation : $3,621,281 %Change : - Education : - Michael H. Ullmann Title : Vice President Tenure : 26 Age : 57 Total Compensation : $5,960,691 %Change : 0.37 Education : - Paulus Stoffels Title : Chief Scientific Officer Tenure : 13 Age : 53 Total Compensation : $18,339,317 %Change : 1.34 Education : - Stephen J. Cosgrove Title : Chief Accounting Officer Tenure : - Age : - Total Compensation : $- %Change : - Education : - Sandra E. Peterson Title : Group Worldwide Chair Tenure : 3 Age : 56 Total Compensation : $7,086,606 %Change : 0.26 Education : - Douglas K. Chia Title : Secretary Tenure : 9 Age : - Total Compensation : $- %Change : - Education : - Johnson & Johnson\n\n10. 09/23/2015 3 Mergent, Inc. Ronald A. Kapusta Title : Division Officer Tenure : 23 Age : 56 Total Compensation : $- %Change : - Education : - Lacey P. Elberg Title : Assistant Secretary Tenure : - Age : - Total Compensation : $- %Change : - Education : - William C. Weldon - Inactive (Stepped Down) Title : Tenure : 44 Age : 66 Total Compensation : $29,838,259 %Change : 0.11 Education : - Christine A. Poon - Inactive (Retired) Title : Vice-Chairman Tenure : 15 Age : 62 Total Compensation : $10,402,493 %Change : -0.01 Education : - Robert J. Darretta - Inactive (Retired) Title : Vice-Chairman Tenure : 47 Age : 68 Total Compensation : $11,263,525 %Change : 1.84 Education : - Russell C. Deyo - Inactive (Retired) Title : Tenure : 30 Age : 65\n\n11. Total Compensation : $8,975,035 %Change : 0.01 Education : - Roger S. Fine - Inactive (Retired) Title : Vice President Tenure : 41 Age : 67 Total Compensation : $- %Change : - Education : - Nicholas J. Valeriani - Inactive (Not Reported) Title : Vice President Tenure : 37 Age : 58 Total Compensation : $- %Change : - Education : - Kaye I. Foster-Cheek - Inactive (Not Reported) Title : Vice President Tenure : 12 Age : 55 Johnson & Johnson 09/23/2015 4 Mergent, Inc. Total Compensation : $- %Change : - Education : - JoAnn Heffernan Heisen - Inactive (Not Reported) Title : Vice President Tenure : 26 Age : 65 Total Compensation : $- %Change : - Education : - Steven M. Rosenberg - Inactive (Not Reported) Title : Secretary\n\n12. Tenure : - Age : - Total Compensation : $- %Change : - Education : - Sherilyn S. McCoy - Inactive (Resigned) Title : Tenure : 33 Age : 56 Total Compensation : $8,733,678 %Change : 0.16 Education : - Colleen A. Goggins - Inactive (Retired) Title : Division Officer Tenure : 34 Age : 60 Total Compensation : $7,738,614 %Change : -0.07 Education : - Donald M. Casey - Inactive (Not Reported) Title : Division Officer Tenure : 30 Age : - Total Compensation : $- %Change : - Education : - Christian A. Koffmann - Inactive (Not Reported) Title : Division Officer Tenure : 26 Age : 66 Total Compensation : $- %Change : - Education : - Joseph C. Scodari - Inactive (Retired) Title : Division Officer Tenure : 16 Age : 62 Total Compensation : $- %Change : - Education : - Per A. Peterson - Inactive (Retired) Title : Division Officer\n\n13. Tenure : 21 Age : 70 Total Compensation : $8,700,118 %Change : 1.84 Education : - Johnson & Johnson 09/23/2015 5 Mergent, Inc. Michael J. Dormer - Inactive (Retired) Title : Division Officer Tenure : 17 Age : 63 Total Compensation : $3,005,443 %Change : 0.68 Education : - Directors Alex Gorsky Title : Chairman Tenure : 27 Age : 55 Total Compensation : $61,989,306 %Change : 2.67 Education : - Mary Sue Coleman Title : Director Tenure : 12 Age : 71 Total Compensation : $284,924 %Change : 0.03 Education : - D. Scott Davis Title : Director Tenure : 1 Age : 63 Total Compensation : $264,924 %Change : - Education : -\n\n14. Ian E. L. Davis Title : Director Tenure : 5 Age : 64 Total Compensation : $58,366 %Change : -0.77 Education : - Susan L. Lindquist Title : Director Tenure : 11 Age : 65 Total Compensation : $286,324 %Change : 0.04 Education : - Mark B. McClellan Title : Director Tenure : 2 Age : 51 Total Compensation : $264,924 %Change : 8.63 Education : - Anne M. Mulcahy Title : Director Tenure : 6 Age : 62 Total Compensation : $324,924 %Change : 0.14 Education : - Johnson & Johnson 09/23/2015 6 Mergent, Inc. William D. Perez Title : Director Tenure : 8 Age : 68 Total Compensation : $284,924 %Change : -0.03 Education : -\n\n15. Charles Prince Title : Director Tenure : 9 Age : 65 Total Compensation : $284,924 %Change : -0.04 Education : - A. Eugene Washington Title : Director Tenure : 3 Age : 64 Total Compensation : $266,924 %Change : 0.02 Education : - Ronald A. Williams Title : Director Tenure : 4 Age : 66 Total Compensation : $284,924 %Change : 0.12 Education : - Mary C. Beckerle Title : Director Tenure : - Age : 60 Total Compensation : $- %Change : - Education : - William C. Weldon - Inactive (Will Not Stand For Re-election) Title : Tenure : 44 Age : 66 Total Compensation : $29,838,259 %Change : 0.11 Education : - Christine A. Poon - Inactive (Retired) Title : Vice-Chairman Tenure : 15 Age : 62 Total Compensation : $10,402,493 %Change : -0.01 Education : -\n\n16. Robert J. Darretta - Inactive (Retired) Title : Vice-Chairman Tenure : 47 Age : 68 Total Compensation : $11,263,525 %Change : 1.84 Education : - James G. Cullen - Inactive (Not Standing For Re-election) Title : Tenure : 20 Age : 72 Johnson & Johnson 09/23/2015 7 Mergent, Inc. Total Compensation : $289,924 %Change : -0.03 Education : - David Satcher - Inactive (Not Standing For Re-election) Title : Tenure : 13 Age : 74 Total Compensation : $203,903 %Change : -0.28 Education : - Leo F. Mullin - Inactive (Not Standing For Re-election) Title : Tenure : 16 Age : 72 Total Compensation : $284,924 %Change : -0.04 Education : - Michael M. E. Johns - Inactive (Not Standing For Re-election) Title : Tenure : 10 Age : 73 Total Compensation : $211,591 %Change : -0.20 Education : -\n\n17. Henry B. Schacht - Inactive (Retired) Title : Tenure : 18 Age : 80 Total Compensation : $- %Change : - Education : - Arnold G. Langbo - Inactive (Resigned) Title : Tenure : 24 Age : 77 Total Compensation : $142,442 %Change : -0.39 Education : - Steven S. Reinemund - Inactive (Resigned) Title : Tenure : 12 Age : 67 Total Compensation : $259,875 %Change : 0.23 Education : - Ann Dibble Jordan - Inactive (Retired) Title : Tenure : 34 Age : 80 Total Compensation : $144,131 %Change : -0.31 Education : - M. Judah Folkman - Inactive (Not Reported) Title : Tenure : 17 Age : 81 Total Compensation : $- %Change : - Education : - Johnson & Johnson 09/23/2015 8 Mergent, Inc.\n\n18. Gerard N. Burrow - Inactive (Not Reported) Title : Tenure : 22 Age : 81 Total Compensation : $- %Change : - Education : - Commitees Audit Committee Anne Mulcahy D. Davis Ian Davis Mary Coleman Benefits & Compensation Committee Charles Prince Ronald Williams William Perez Corporate Governance & Nominating Committee Anne Mulcahy Charles Prince William Perez Finance Committee Alex Gorsky Anne Mulcahy Public Policy Committee Science & Technology Committee A. Washington Ian Davis Mark McClellan Mary Coleman\n\n19. Susan Lindquist Executive Compensation Officers Alex Gorsky Compensation History Year Values in USD 2014 2013 2012 Salary 1,500,000 1,453,846 1,087,188 Stock Awards 9,467,380 5,988,975 2,790,229 Option Awards 41,168,139 2,669,999 1,482,631 Non-Equity Incentive Plan 5,018,779 4,867,361 3,407,287 Johnson & Johnson 09/23/2015 9 Mergent, Inc. Year Values in USD 2014 2013 2012 Compensation Change in Pension Value & 4,606,142 1,739,000 2,050,000 Non-Qualified Deferred Comp. Earni All Other Compensation 228,866 191,779 159,774 Total Compensation 61,989,306 16,910,960 10,977,109 Dominic J. Caruso Compensation History Year Values in USD 2014 2013 2012 Salary 878,115 842,308 796,385 Stock Awards 3,271,853 2,663,229 2,089,563 Option Awards 1,332,376 1,139,999 1,110,303\n\n20. Non-Equity Incentive Plan 3,234,152 3,222,866 3,014,577 Compensation Change in Pension Value & 1,511,238 252,000 915,000 Non-Qualified Deferred Comp. Earni All Other Compensation 121,299 112,911 84,009 Total Compensation 10,349,033 8,233,313 8,009,837 Peter M. Fasolo Compensation History Year Values in USD 2012 Salary 534,769 Stock Awards 1,387,098 Option Awards 737,042 Non-Equity Incentive Plan 715,209 Compensation Change in Pension Value & 214,000 Non-Qualified Deferred Comp. Earni All Other Compensation 33,163 Total Compensation 3,621,281 Michael H. Ullmann Compensation History Year Values in USD 2014 2013 Salary 591,346 542,308 Stock Awards 1,615,191 1,390,982 Option Awards 721,877 656,248 Non-Equity Incentive Plan 1,502,105 1,348,953 Compensation Change in Pension Value & 1,494,001 394,000\n\n21. Johnson & Johnson 09/23/2015 10 Mergent, Inc. Year Values in USD 2014 2013 Non-Qualified Deferred Comp. Earni All Other Compensation 36,171 30,845 Total Compensation 5,960,691 4,363,336 Paulus Stoffels Compensation History Year Values in USD 2014 2013 2012 Salary 1,075,423 952,923 825,385 Stock Awards 10,690,520 2,580,466 1,926,252 Option Awards 1,307,669 1,109,999 1,023,570 Non-Equity Incentive Plan 2,573,450 2,416,809 2,305,251 Compensation Change in Pension Value & 2,267,167 357,000 1,095,000 Non-Qualified Deferred Comp. Earni All Other Compensation 425,088 404,802 161,466 Total Compensation 18,339,317 7,821,999 7,336,924 Stephen J. Cosgrove Sandra E. Peterson Compensation History Year Values in USD 2014 2013 2012 Salary 841,346 800,000 46,154 Bonus N/A 1,900,000 300,000 Stock Awards 2,833,545 635,867 4,300,017 Option Awards 1,368,001 299,998 N/A Non-Equity Incentive Plan 1,400,000 1,200,000 N/A\n\n22. Compensation Change in Pension Value & 451,000 274,000 N/A Non-Qualified Deferred Comp. Earni All Other Compensation 192,714 527,396 52,679 Total Compensation 7,086,606 5,637,261 4,698,850 Douglas K. Chia Ronald A. Kapusta Lacey P. Elberg Johnson & Johnson 09/23/2015 11 Mergent, Inc. William C. Weldon Compensation History Year Values in USD 2012 2011 2010 Salary 1,320,578 1,907,215 1,851,154 Bonus N/A N/A N/A Other Annual Compensation/Fees N/A N/A N/A Stock Awards 7,565,328 2,608,694 2,773,851 Option Awards 4,019,999 4,189,483 4,713,177 Restricted Stock Units N/A N/A N/A Underlying Options/SARs (# of N/A N/A N/A Securities) Non-Equity Incentive Plan 13,447,666 14,336,394 12,043,200 Compensation Change in Pension Value & 3,250,000 3,435,000 7,084,673 Non-Qualified Deferred Comp. Earni All Other Compensation 234,688 321,153 254,436\n\n23. Total Compensation 29,838,259 26,797,939 28,720,491 Christine A. Poon Compensation History Year Values in USD 2008 2007 2006 Salary 1,042,404 1,008,846 967,308 Bonus N/A N/A N/A Other Annual Compensation/Fees N/A N/A N/A Stock Awards 912,366 613,667 270,596 Option Awards 2,172,123 2,557,952 2,504,609 Restricted Stock Units N/A N/A N/A Underlying Options/SARs (# of N/A N/A N/A Securities) Non-Equity Incentive Plan 3,721,500 3,718,000 2,389,600 Compensation Change in Pension Value & 1,260,949 1,046,961 1,017,184 Non-Qualified Deferred Comp. Earni All Other Compensation 1,293,151 1,198,421 1,021,083 Total Compensation 10,402,493 10,143,847 8,170,380 Robert J. Darretta Compensation History Year Values in USD 2006 2005 2004 Salary 1,023,846 983,846 950,000 Bonus N/A 891,000 874,500 Other Annual Compensation/Fees N/A 1,230,850 1,012,660 Stock Awards 626,226 N/A N/A Johnson & Johnson\n\n24. 09/23/2015 12 Mergent, Inc. Year Values in USD 2006 2005 2004 Option Awards 3,229,546 N/A N/A Restricted Stock Units N/A 674,994 N/A Underlying Options/SARs (# of N/A 138,841 160,000 Securities) Non-Equity Incentive Plan 2,574,880 N/A N/A Compensation Change in Pension Value & 2,231,163 N/A N/A Non-Qualified Deferred Comp. Earni All Other Compensation 1,577,864 44,273 42,750 Total Compensation 11,263,525 3,824,963 2,879,910 Russell C. Deyo Compensation History Year Values in USD 2011 2010 2009 Salary 895,269 867,377 831,838 Bonus N/A N/A N/A Other Annual Compensation/Fees N/A N/A N/A Stock Awards 783,714 622,707 611,372 Option Awards 1,258,614 1,058,060 1,159,245 Non-Equity Incentive Plan 3,967,694 3,831,820 3,608,760 Compensation Change in Pension Value & 1,999,000 2,359,313 2,374,644 Non-Qualified Deferred Comp. Earni Long-Term Compensation N/A N/A N/A All Other Compensation 70,744 112,688 45,535 Total Compensation 8,975,035 8,851,965 8,631,394 Roger S. Fine Nicholas J. Valeriani\n\n25. Kaye I. Foster-Cheek JoAnn Heffernan Heisen Steven M. Rosenberg Sherilyn S. McCoy Compensation History Johnson & Johnson 09/23/2015 13 Mergent, Inc. Year Values in USD 2011 2010 2009 Salary 897,806 780,377 747,731 Stock Awards 705,437 679,311 407,599 Option Awards 1,132,912 1,154,247 772,833 Non-Equity Incentive Plan 3,924,807 3,221,760 2,626,630 Compensation Change in Pension Value & 2,008,000 1,602,966 1,188,351 Non-Qualified Deferred Comp. Earni All Other Compensation 64,716 78,443 36,890 Total Compensation 8,733,678 7,517,104 5,780,034 Colleen A. Goggins Compensation History Year Values in USD 2010 2009 2008 Salary 823,031 795,854 766,635 Stock Awards 634,107 634,037 630,240 Option Awards 1,077,431 1,202,179 1,022,731 Non-Equity Incentive Plan 3,404,650 3,784,070 3,687,885\n\n26. Compensation Change in Pension Value & 1,737,017 1,840,303 1,600,850 Non-Qualified Deferred Comp. Earni All Other Compensation 62,378 60,453 69,844 Total Compensation 7,738,614 8,316,896 7,778,185 Donald M. Casey Christian A. Koffmann Joseph C. Scodari Per A. Peterson Compensation History Year Values in USD 2006 2005 2004 Salary 830,692 801,077 761,808 Bonus N/A 750,268 798,750 Other Annual Compensation/Fees N/A 721,042 493,044 Stock Awards 579,841 N/A N/A Option Awards 3,052,229 N/A N/A Restricted Stock Units N/A 624,996 N/A Underlying Options/SARs (# of N/A 128,557 150,000 Securities) Non-Equity Incentive Plan 2,312,400 N/A N/A Johnson & Johnson 09/23/2015 14 Mergent, Inc. Year Values in USD 2006 2005 2004 Compensation Change in Pension Value & 1,041,564 N/A N/A\n\n27. Non-Qualified Deferred Comp. Earni All Other Compensation 883,392 36,048 34,281 Total Compensation 8,700,118 2,933,431 2,087,883 Michael J. Dormer Compensation History Year Values in USD 2005 2004 2003 Salary 675,215 650,338 644,846 Bonus 940,500 553,875 515,000 Other Annual Compensation/Fees 605,790 449,006 384,024 Restricted Stock Units 624,996 N/A N/A Underlying Options/SARs (# of 128,557 110,000 120,000 Securities) All Other Compensation 30,385 29,265 29,018 Total Compensation 2,876,886 1,682,484 1,572,888 Directors Alex Gorsky Compensation History Year Values in USD 2014 2013 2012 Salary 1,500,000 1,453,846 1,087,188 Stock Awards 9,467,380 5,988,975 2,790,229 Option Awards 41,168,139 2,669,999 1,482,631 Non-Equity Incentive Plan 5,018,779 4,867,361 3,407,287 Compensation Change in Pension Value & 4,606,142 1,739,000 2,050,000 Non-Qualified Deferred Comp. Earni All Other Compensation 228,866 191,779 159,774 Total Compensation 61,989,306 16,910,960 10,977,109 Mary Sue Coleman\n\n28. Compensation History Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 110,000 110,000 110,000 Stock Awards 154,924 144,989 144,913 All Other Compensation 20,000 20,710 20,000 Total Compensation 284,924 275,699 274,913 Johnson & Johnson 09/23/2015 15 Mergent, Inc. D. Scott Davis Compensation History Year Values in USD 2014 Other Annual Compensation/Fees 110,000 Stock Awards 154,924 Total Compensation 264,924 Ian E. L. Davis Compensation History Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 58,366 110,000 110,000 Stock Awards N/A 144,989 144,913 Total Compensation 58,366 254,989 254,913 Susan L. Lindquist Compensation History\n\n29. Year Values in USD 2014 2013 2012 Salary N/A N/A N/A Other Annual Compensation/Fees 130,000 130,000 110,000 Stock Awards 154,924 144,989 144,913 All Other Compensation 1,400 1,631 4,000 Total Compensation 286,324 276,620 258,913 Mark B. McClellan Compensation History Year Values in USD 2014 2013 Other Annual Compensation/Fees 110,000 27,500 Stock Awards 154,924 N/A Total Compensation 264,924 27,500 Anne M. Mulcahy Compensation History Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 140,000 140,000 110,000 Stock Awards 164,924 144,989 144,913 All Other Compensation 20,000 N/A N/A Total Compensation 324,924 284,989 254,913 Johnson & Johnson 09/23/2015 16 Mergent, Inc. William D. Perez Compensation History\n\n30. Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 130,000 130,000 130,000 Stock Awards 154,924 144,989 144,913 All Other Compensation N/A 20,000 20,000 Total Compensation 284,924 294,989 294,913 Charles Prince Compensation History Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 130,000 130,000 130,000 Stock Awards 154,924 144,989 144,913 All Other Compensation N/A 20,524 10,000 Total Compensation 284,924 295,513 284,913 A. Eugene Washington Compensation History Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 110,000 110,000 9,167 Stock Awards 154,924 144,989 N/A All Other Compensation 2,000 5,772 N/A Total Compensation 266,924 260,761 9,167 Ronald A. Williams Compensation History Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 110,000 110,000 110,000 Stock Awards 154,924 144,989 144,913 All Other Compensation 20,000 N/A N/A Total Compensation 284,924 254,989 254,913\n\n31. Mary C. Beckerle William C. Weldon Compensation History Johnson & Johnson 09/23/2015 17 Mergent, Inc. Year Values in USD 2012 2011 2010 Salary 1,320,578 1,907,215 1,851,154 Bonus N/A N/A N/A Other Annual Compensation/Fees N/A N/A N/A Stock Awards 7,565,328 2,608,694 2,773,851 Option Awards 4,019,999 4,189,483 4,713,177 Restricted Stock Units N/A N/A N/A Underlying Options/SARs (# of N/A N/A N/A Securities) Non-Equity Incentive Plan 13,447,666 14,336,394 12,043,200 Compensation Change in Pension Value & 3,250,000 3,435,000 7,084,673 Non-Qualified Deferred Comp. Earni All Other Compensation 234,688 321,153 254,436 Total Compensation 29,838,259 26,797,939 28,720,491 Christine A. Poon Compensation History Year Values in USD 2008 2007 2006 Salary 1,042,404 1,008,846 967,308 Bonus N/A N/A N/A Other Annual Compensation/Fees N/A N/A N/A\n\n32. Stock Awards 912,366 613,667 270,596 Option Awards 2,172,123 2,557,952 2,504,609 Restricted Stock Units N/A N/A N/A Underlying Options/SARs (# of N/A N/A N/A Securities) Non-Equity Incentive Plan 3,721,500 3,718,000 2,389,600 Compensation Change in Pension Value & 1,260,949 1,046,961 1,017,184 Non-Qualified Deferred Comp. Earni All Other Compensation 1,293,151 1,198,421 1,021,083 Total Compensation 10,402,493 10,143,847 8,170,380 Robert J. Darretta Compensation History Year Values in USD 2006 2005 2004 Salary 1,023,846 983,846 950,000 Bonus N/A 891,000 874,500 Other Annual Compensation/Fees N/A 1,230,850 1,012,660 Stock Awards 626,226 N/A N/A Option Awards 3,229,546 N/A N/A Restricted Stock Units N/A 674,994 N/A Underlying Options/SARs (# of N/A 138,841 160,000 Securities) Johnson & Johnson 09/23/2015 18 Mergent, Inc. Year Values in USD 2006 2005 2004 Non-Equity Incentive Plan 2,574,880 N/A N/A Compensation Change in Pension Value & 2,231,163 N/A N/A\n\n33. Non-Qualified Deferred Comp. Earni All Other Compensation 1,577,864 44,273 42,750 Total Compensation 11,263,525 3,824,963 2,879,910 James G. Cullen Compensation History Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 135,000 135,000 165,000 Stock Awards 154,924 144,989 144,913 All Other Compensation N/A 20,000 N/A Total Compensation 289,924 299,989 309,913 David Satcher Compensation History Year Values in USD 2013 2012 2011 Other Annual Compensation/Fees 36,667 130,000 130,000 Stock Awards 144,989 144,913 99,974 All Other Compensation 22,247 10,000 20,000 Total Compensation 203,903 284,913 249,974 Leo F. Mullin Compensation History Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 130,000 130,000 130,000 Stock Awards 154,924 144,989 144,913 All Other Compensation N/A 21,884 16,666 Total Compensation 284,924 296,873 291,579 Michael M. E. Johns\n\n34. Compensation History Year Values in USD 2014 2013 2012 Other Annual Compensation/Fees 36,667 110,000 110,000 Stock Awards 154,924 144,989 144,913 All Other Compensation 20,000 10,000 20,000 Total Compensation 211,591 264,989 274,913 Johnson & Johnson 09/23/2015 19 Mergent, Inc. Henry B. Schacht Arnold G. Langbo Compensation History Year Values in USD 2010 2009 2008 Other Annual Compensation/Fees 30,000 120,000 120,000 Stock Awards 99,942 99,978 99,973 All Other Compensation 12,500 12,500 29,344 Total Compensation 142,442 232,478 249,317 Steven S. Reinemund Compensation History Year Values in USD 2008 2007 2006 Other Annual Compensation/Fees 38,000 103,167 95,000 Stock Awards 99,973 99,939 99,995 All Other Compensation 121,902 7,692 4,692 Total Compensation 259,875 210,798 199,687\n\n35. Ann Dibble Jordan Compensation History Year Values in USD 2007 2006 Other Annual Compensation/Fees 36,500 105,000 Stock Awards 99,939 99,995 All Other Compensation 7,692 4,692 Total Compensation 144,131 209,687 M. Judah Folkman Gerard N. Burrow Insider Holdings Holdings Summary Total Insiders 41 Total Direct Shares 3,212,143 Total Indirect Shares 489,557 % Held By Insiders 0.12% Johnson & Johnson 09/23/2015 20 Mergent, Inc. Filer's Name Relation Direct Date Prince Charles Director 08/06/2015 Stoffels Paulus Chief Scientific Officer 04/28/2015 Fasolo Peter VP, Global Human Resources 03/05/2015 Gorsky Alex Chairman, CEO 02/09/2015 Caruso Dominic J VP, Finance; CFO 02/09/2015 Cosgrove Stephen J Corporate Controller 01/16/2015 Ullmann Michael H VP, General Counsel 01/16/2015\n\n36. Peterson Sandra E Group Worldwide Chairman 12/17/2014 Cullen James Director 09/10/2014 Coleman Mary Sue Director 05/08/2014 Perez William D Director 11/05/2013 Mullin Leo F Director 10/16/2013 Weldon William C Former Chairman of the Board 02/08/2013 Satcher David Director 02/05/2013 Lindquist Susan L Director 12/07/2012 Deyo Russell C VP, General Counsel 02/22/2012 Davis Ian Director 02/13/2012 Johns Michael M E Director 02/13/2012 Mulcahy Anne M Director 02/13/2012 Williams Ronald A Director 02/13/2012 Mccoy Sherilyn S Member, Executive Committee 02/09/2012 Goggins Colleen A Member, Executive Committee 01/10/2011 Langbo Arnold G Director 02/08/2010 Foster-Cheek Kaye I VP, Human Resources 12/31/2009 Valeriani Nicholas J VP, Strategy & Growth, Member, Executive 08/25/2009 Committee, Director Casey Donald M Jr. Member, Executive Committee 02/13/2009 Poon Christine A Vice Chairman, Director 02/13/2009 Scodari Joseph C Retired Exec Committee Member 05/28/2008 Reinemund Steven Director 02/11/2008 Peterson Per A Executive Committee Member 02/16/2007 Jordan Ann Dibble Director 02/12/2007 Johnson & Johnson 09/23/2015 21 Mergent, Inc. Filer's Name Relation Direct Date Darretta Robert J Vice Chairman, Director 12/15/2006\n\n37. Dormer Michael J Member, Executive Committee 10/24/2006 Heisen Joann Heffernan VP, Chief Information Officer 12/30/2005 Schacht Henry B Director 04/28/2005 Burrow Gerard N Director 04/28/2005 Folkman M Judah Director 04/28/2005 Perkins Brian D Former Member Exec Committee 09/03/2004 Fine Roger S Retired Exec Committee Member 08/31/2004 Lenehan James T Former Vice Chairman/Director 05/31/2004 Wilson Robert N Retired Director/Vice Chairman 08/19/2003 Filer's Name Direct Shares Indirect Date Indirect Shares Prince Charles 25,645 08/06/2015 800 Stoffels Paulus 94,473 0 Fasolo Peter 32,588 01/10/2011 0 Gorsky Alex 113,361 02/09/2015 1,417 Caruso Dominic J 88,734 02/09/2015 301 Cosgrove Stephen J 97,011 01/16/2015 2,133 Ullmann Michael H 72,251 01/16/2015 1,425 Peterson Sandra E 19,042 12/17/2013 0 Cullen James 1,489 10/21/2010 0 Coleman Mary Sue 12,601 0 Perez William D 8,122 11/05/2013 11,500 Mullin Leo F 26,195 10/16/2013 1,200 Weldon William C 307,273 02/08/2013 79,318 Satcher David 15,393 04/28/2005 0 Lindquist Susan L 14,605 02/02/2004 0 Deyo Russell C 141,443 02/22/2012 25,275 Davis Ian 4,193 07/19/2010 0 Johns Michael M E 14,356 0 Mulcahy Anne M 5,789 10/22/2009 0 Williams Ronald A 3,650 06/14/2011 0 Mccoy Sherilyn S 56,307 02/09/2012 18,608 Goggins Colleen A 107,832 01/10/2011 1,211 Langbo Arnold G 8,166 02/08/2010 1,600 Foster-Cheek Kaye I 4,583 12/31/2009 1,214\n\n38. Valeriani Nicholas J 57,353 09/30/2009 10,076 Casey Donald M Jr. 22,536 02/13/2009 22,387 Poon Christine A 55,711 02/13/2009 178 Scodari Joseph C 18,646 04/30/2008 2,845 Reinemund Steven 7,567 0 Peterson Per A 16,043 02/16/2007 16,000 Jordan Ann Dibble 13,290 03/11/2003 0 Darretta Robert J 207,118 12/29/2006 1,938 Dormer Michael J 18,499 09/29/2006 878 Heisen Joann Heffernan 161,864 12/30/2005 8,176 Schacht Henry B 3,900 04/28/2005 0 Burrow Gerard N 10,267 04/28/2005 400 Folkman M Judah 3,811 11/05/2004 0 Johnson & Johnson 09/23/2015 22 Mergent, Inc. Filer's Name Direct Shares Indirect Date Indirect Shares Perkins Brian D 61,899 08/31/2004 1,734 Fine Roger S 191,226 08/31/2004 57,386 Lenehan James T 198,157 05/31/2004 10,525 Wilson Robert N 889,154 08/19/2003 211,032 Source: J3 Information Services Group Insider Trades 3 Months Summary (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months Total Shares Bought 2,500 233,683 603,320 798,929\n\n39. Total Buy Value 248,132 15,229,586 24,454,133 31,316,256 Total People Bought 1 2 8 9 Total Buy Transactions 1 3 21 41 Total Shares Sold 0 187,250 425,689 562,062 Total Sell Value 0 18,862,142 43,273,070 56,432,688 Total People Sold 0 1 7 9 Total Sell Transactions 0 1 16 32 End Date 06/23/2015 03/23/2015 09/23/2014 09/23/2013 Filer's Name Relation Title Off - Dir - 10% Trans. Date Form Action Price Mkt Value Prince Charles Director 1 - 1 - 0 08/06/2015 4 B 99.25 248,132 Filer's Name D/I Shares Holdings Rank 3m +/- Prince Charles D 2,500 25,645 (4.27) Transaction Ownership Code Key : Code Key : A - Acquired NO - UNKNOWN (added 06/04/2012) D AB - Automatic Buy NP - Unknown (added 02/19/2013) I Johnson & Johnson 09/23/2015 23 Mergent, Inc. Transaction Ownership Code Key : Code Key : AS - Automatic Sell OE - Options Exercised B - Buy PB - Private Buy D - Disposed PS - Private Sell IO - Initital Ownership S - Sell - Direct\n\n40. - Indirect Source: J3 Information Services Group 09/23/2015 1 Mergent, Inc. Johnson & Johnson General Company Information Principal Office One Johnson & Johnson Plaza New Brunswick, NJ 08933 USA Phone 732 524-0400 Fax 732 214-0332 Auditor PricewaterhouseCoopers LLP Number of Employees 126,500 (Approximate Full-Time as of 12/31/2014) Country of Incorporation United States Exchange And Ticker NYS : JNJ Primary SIC 2834 : Pharmaceutical preparations\n\n41. Company Website www.jnj.com Primary NAICS 325412 : Pharmaceutical Preparation Manufacturing Closing Stock Price 93.24 (as of 09/22/2015) Incorporated November 1887 , NJ, United States Mergent Dividend Achiever Yes, # of Years: 46 Number of Shareholders 162,062 (record) (as of 02/17/2015) Business Summary Johnson & Johnson is a holding company. Through its subsidiaries, Co. is organized into three segments. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopaedic, surgical care, specialty surgery, cardiovascular care, diagnostics, diabetes care, and vision care markets, which are distributed to wholesalers, hospitals and retailers.\n\n42. Johnson & Johnson 09/23/2015 2 Mergent, Inc. Company Details Pricing Summary Time Period: 1 week Yesterday 5 Days 30 Days Close 93.24 93.39 92.82 Volume 10,618,620.00 14,211,147.00 25,633,357.00 52 Week High/Low : 109.07 - 90.73 % Price Change (100 Days) : -4.36 200-Day Moving Avg. : 98.98 Company News 12:02PM, 23 September 2015 - Report: J&J had plan to block more FDA restrictions on Tylenol - BioPharma Dive 11:11AM, 23 September 2015 - FDA Was Pressured By J&J Not to Address Tylenol Liver Damage Risk: Report - AboutLawsuits.com 11:10AM, 23 September 2015 - U of Toronto to collaborate with Johnson & Johnson on health start-ups - Technology Transfer Tactics 9:52AM, 23 September 2015 - Nike, Johnson & Johnson, Starbucks, And Others Join Pledge For 100% Renewable Electricity - CleanTechnica 9:00AM, 23 September 2015 - Dishman gets licence from JJ to make TB drug raw material - Money Control\n\n43. 8:19AM, 23 September 2015 - Risperdal Litigation Pioneer Stephen Sheller Featured in \"DocuSerial\" about Johnson & Johnson, \"America's Most Admired Lawbreaker\" by Steve Brill - PR Newswire 3:21AM, 23 September 2015 - Dishman Pharma to make TB drug exclusively for JJ - Money Control 11:10PM, 22 September 2015 - Fortune 500 listed companies pledge to use 100% renewable electricity - Blue and Green Tomorrow 3:00PM, 22 September 2015 - Johnson & Johnson: A Gold Standard Dividend Stock - Seeking Alpha 11:03AM, 22 September 2015 - J&J faces Tylenol lobbying allegations in first case to go to trial over med Johnson & Johnson 09/23/2015 3 Mergent, Inc. - FiercePharma Corporate Events Earnings Announcement Data - October 13 2015 : On Oct. 13, 2015, Co. announced its 3rd quarter earnings before market (confirmed). Conference Call Announcements - October 13 2015 : On Oct. 13, 2015, Co. scheduled a conference call at 12:30pm. Conference Call Announcements - July 14 2015 : On July 14, 2015, Co. scheduled a conference call at 12:30pm. Earnings Announcement Data - July 14 2015 : On July 14, 2015, Co. announced its 2nd quarter earnings (confirmed).\n\n44. Earnings Announcement Data - April 14 2015 : On Apr. 14, 2015, Co. announced its 1st quarter earnings before market (confirmed). Earnings Announcement Data - April 14 2015 : On Apr. 14, 2015, Co. announced its 1st quarter earnings before market (confirmed). Conference Call Announcements - April 14 2015 : On Apr. 14, 2015, Co. scheduled a conference call at 12:30pm. Key Executives Alex Gorsky Age Salary Chairman,Chief Executive Officer 55 1,500,000 Dominic Caruso Age Salary Vice President,Chief Financial Officer 57 878,115 Peter Fasolo Age Salary Vice President 52 534,769 Michael Ullmann Age Salary Vice President,General Counsel 57 591,346 Paulus Stoffels Age Salary Chief Scientific Officer 53 1,075,423 Key Financials (In USD as of 06/28/2015) Income Statement Revenue 71,882m Net Income 16,106m EPS from Continuing Operations 5.69 EPS - Net Income - Diluted 5.69 Revenue per Share 25.93 Balance Sheet Total Assets 132,036m\n\n45. Total Liabilities 60,905m Shareholders' Equity 71,131m Total Assets per Share 47.68 Net Assets per Share 25.69 Johnson & Johnson 09/23/2015 4 Mergent, Inc. Cash Flows Cash from Operations 17,091m Cash from Investing -7,530m Cash from Financing -12,065m Capital Expenditures 3,555m Cash Flow per Share 6.08 Financial Highlights Financial Highlights as of 12/28/2014 in USD Income Statement (In Thousands) Total Revenue 74,331,000 EBITDA 24,927,000 Operating Income 20,959,000 Net Income 16,323,000 Revenue per Share 26.48 EPS from Continuing Operations 5.70 EPS - Net Income - Diluted 5.70 Share Outstanding 2,783,223 Weighted Average Shares Outstanding - Basic 2,815,200 Weighted Average Shares Outstanding - Diluted 2,863,900 Earnings per Share - Basic 5.80 Balance Sheet (In Thousands) Total Assets 131,119,000 Current Assets 59,311,000\n\n46. Total Liabilities 61,367,000 Long Term Debt 15,122,000 Stockholders' Equity 69,752,000 Total Assets per Share 47.11 Current Liabilities 25,085,000 Net Assets per Share 25.06 Cash Flow Statement (In Thousands) Cash from Operations 18,471,000 Cash from Investing (12,305,000) Cash from Financing (12,260,000) Capital Expenditures 3,714,000 Cash Flow per Share 6.45 Cash & Cash Equivalents, Beginning of Year 20,927,000 Cash & Cash Equivalents, End of Year 14,523,000 Stock Price and Valuation (Data as of 09/22/2015) Market Cap(mil) 258,191 Share Outstanding(000's) 2,769,106 PE Ratio 16.3866 Dividend Per Share(TTM) 2.9 Earning Per Share(TTM) 5.78 Last Closing Price 93.24 Previous Trading Day Range 91.88 - 93.44 52 Week Range 90.73 - 109.07 7 Day Average Closing Price 93.94 30 Day Average Closing Price 93.44 Johnson & Johnson 09/23/2015 5 Mergent, Inc. 200 Day Average Closing Price 98.98 Beta 0.55 High Price Last 3 Mos. 101.11 Low Price Last 3 Mos. 90.73\n\n47. Avg Daily Volume Last 3 Mos. 8,391,457.25 Management Effectiveness Revenue per Employee 589,211 Net Income per Employee 129,390 ROA % (Net) 12.41 ROE % (Net) 22.76 ROI % (Operating) 23.26 Profitability Ratios Gross Margin 69.40 Operating Margin 28.20 EBITDA Margin % 33.54 Calculated Tax Rate % 20.62 Profit Margin (TTM) 21.96 Valuation Ratios Price/Earnings (TTM) 18.06 Price/Book (TTM) 4.19 Price/Cash Flow(TTM) 15.97 Asset Management Total Asset Turnover 0.57 Receivables Turnover 6.57 Inventory Turnover 2.83 Property Plant & Equip Turnover 4.54 Cash & Equivalents Turnover 4.21 Debt Management Interest Coverage 44.98 Long Term Debt/Equity 0.22 Long Term Debt as % of Invested Capital 17.08 Total Debt/Equity 0.27 Accounts Payable Turnover 10.73 Accrued Expenses Turnover 5.25 Liquidity Indicators Quick Ratio 1.76 Current Ratio 2.36 Net Current Assets as % of Total Assets 26.10 Free Cash Flow per Share 5.26\n\n48. Revenue to Assets 0.57 Consensus Estimates 2015Ae 2015Q3e 2015Q4e Earnings Per Share 6.16 1.46 1.44 Revenue 70,714.15 17,502.00 18,012.96 EBITDA 23,750.63 5,691.94 5,272.88 Property Co. maintains its principal executive offices in New Brunswick, NJ. Co.'s subsidiaries operate 134 manufacturing facilities occupying approx. 21,500,000 sq. ft. of floor space. Johnson & Johnson 09/23/2015 6 Mergent, Inc. The following table sets forth information regarding the manufacturing facilities used by the industry segments of Co.'s business as of Dec. 28, 2014: Segment [1]Sq. Ft. Consumer 7,213 Pharmaceutical 7,404 Medical Devices 6,850 Total 21,467 [1]In thousands The following table sets forth information regarding the locations of Co.'s manufacturing facilities by geographic areas as of Dec. 28, 2014:\n\n49. Geographic Area [1]Sq. Ft. U.S. (42) 5,892 Europe (41) 7,673 Western Hemisphere, excluding U.S. (15) 3,005 Africa, Asia and Pacific (36) 4,897 Total 21,467 [1]In thousands In addition, Co. and its subsidiaries maintain several office and warehouse facilities throughout the world. Principal Executive Offices One Johnson & Johnson Plaza New Brunswick, NJ 08933 United States Subsidiaries SUBSIDIARY NAME PERCENT OWNED COUNTRY Subsidiaries Subsidiaries Acclarent, Inc. 100% United States ALZA Corporation 100% United States Animas Corporation 100% United States Aragon Pharmaceuticals, Inc. 100% United States Biosense Webster, Inc. 100% United States CNA Development LLC 100% United States Codman & Shurtleff, Inc. 100% United States Cordis Corporation 100% United States Cordis International Corporation 100% United States Cordis LLC 100% United States DePuy Mitek Holding Corporation 100% United States DePuy Mitek, LLC 100% United States DePuy Orthopaedics, Inc. 100% United States DePuy Products, Inc. 100% United States\n\n50. Johnson & Johnson 09/23/2015 7 Mergent, Inc. SUBSIDIARY NAME PERCENT OWNED COUNTRY DePuy Spine, LLC 100% United States DePuy Synthes Sales, Inc. 100% United States DePuy Synthes, Inc. 100% United States Diabetes Diagnostics, Inc. 100% United States Ethicon Endo-Surgery, Inc. 100% United States Ethicon Endo-Surgery, LLC 100% United States Ethicon LLC 100% United States Ethicon US, LLC 100% United States Ethicon, Inc. 100% United States Flexible Stenting Solution s, Inc. 100% United States J&J Holdings (Nevada), Inc. 100% United States Janssen Alzheimer Immunotherapy 100% United States Research & Development, LLC Janssen Biotech, Inc. 100% United States Janssen Global Services, LLC 100% United States Janssen Oncology, Inc. 100% United States Janssen Ortho LLC 100% United States Janssen Pharmaceuticals, Inc. 100% United States\n\n51. Janssen Products, LP 100% United States Janssen Research & 100% United States Development, LLC Janssen Scientific Affairs, LLC 100% United States Janssen Supply Group, LLC 100% United States Janssen-Cilag Manufacturing, LLC 100% United States JJHC, LLC 100% United States JNJ International Investment LLC 100% United States Johnson & Johnson (Middle 100% United States East) Inc. Johnson & Johnson Consumer 100% United States Companies, Inc. Johnson & Johnson Development 100% United States Corporation Johnson & Johnson Finance 100% United States Corporation Johnson & Johnson Health Care 100% United States Systems Inc. Johnson & Johnson International 100% United States Johnson & Johnson Japan Inc. 100% United States Johnson & Johnson Sales and 100% United States Logistics Company, LLC Johnson & Johnson Services, 100% United States Inc. Johnson & Johnson Urban 100% United States\n\n52. Renewal Associates Johnson & Johnson Vision Care, 100% United States Inc. JOM Pharmaceutical Services, Inc. 100% United States LifeScan LLC 100% United States LifeScan Products, LLC 100% United States LifeScan, Inc. 100% United States Johnson & Johnson 09/23/2015 8 Mergent, Inc. SUBSIDIARY NAME PERCENT OWNED COUNTRY McNeil Consumer Pharmaceuticals Co. 100% United States McNeil Healthcare LLC 100% United States McNeil LA LLC 100% United States McNEIL MMP, LLC 100% United States McNeil Nutritionals, LLC 100% United States McNEIL-PPC, Inc. 100% United States Mentor Texas L.P. 100% United States Mentor Worldwide LLC 100% United States Micro Typing Systems, Inc. 100% United States Micrus Endovascular LLC 100% United States\n\n53. Middlesex Assurance Company Limited 100% United States Neutrogena Corporation 100% United States Noramco, Inc. 100% United States OMJ Pharmaceuticals, Inc. 100% United States Omrix Biopharmaceuticals, Inc. 100% United States Ortho Biologics LLC 100% United States Ortho-Clinical Diagnostics, Inc. 100% United States Rutan Realty LLC 100% United States Scios LLC 100% United States SterilMed, Inc. 100% United States Synthes USA Products, LLC 100% United States Synthes USA, LLC 100% United States Synthes, Inc. 100% United States The Anspach Effort, LLC 100% United States Wellness & Prevention, Inc. 100% United States Almaco Holding AG 100% Switzerland Apsis 100% France Apsis Germany GmbH 100% Germany Beijing Dabao Cosmetics Co., Ltd. 100% China (Peoples Rep. Of) Berna Biotech Korea Corporation 100% Korea (South) Berna Rhein B.V. 100% Netherlands Biosense Webster (Israel) Ltd. 100% Israel Cilag Advanced Technologies GmbH 100% Switzerland\n\n54. Cilag AG 100% Switzerland Cilag GmbH International 100% Switzerland Cilag Holding AG 100% Switzerland Cilag Pharmaceuticals GmbH 100% Switzerland Cilag Products GmbH 100% Switzerland Cordis de Mexico, S.A. de C.V. 100% Mexico Cordis Europa NV 100% Netherlands Corimmun GmbH 100% Germany Crucell Holland B.V. 100% Netherlands Crucell N.V. 100% Netherlands Crucell Sweden AB 100% Sweden Crucell Switzerland AG 100% Switzerland DePuy (Ireland) 100% Ireland DePuy France 100% France DePuy International (Holdings) 100% United Kingdom Limited Johnson & Johnson 09/23/2015 9 Mergent, Inc. SUBSIDIARY NAME PERCENT OWNED COUNTRY DePuy International Limited 100% United Kingdom\n\n55. DePuy Medical Private Limited 100% India DePuy Mitek Sarl 100% Switzerland DePuy Synthes Apollo Limited 100% Ireland DePuy Synthes Eos Limited 100% Ireland DePuy Synthes Gorgan Limited 100% Ireland DePuy Synthes Jason Limited 100% Ireland DePuy Synthes Leto S.A.R.L. 100% Ireland DePuy UK Holdings Limited 100% United Kingdom EES Holdings de Mexico, S. de R.L. 100% Mexico de C.V. Ethicon 100% France Ethicon Ireland 100% Ireland Ethicon PR Holdings 100% Ireland Ethicon Women's Health & 100% Switzerland Urology Sarl Ethnor Farmaceutica, S.A. 100% Venezuela FMS Future Medical System SA 100% Switzerland GMED Healthcare BVBA 100% Belgium J.C. General Services CVBA 100% Belgium Janssen Alzheimer Immunotherapy 100% Ireland Janssen Alzheimer Immunotherapy 100% Ireland (Holding) Limited Janssen Biologics (Ireland) 100% Ireland Janssen Biologics B.V. 100% Netherlands Janssen Cilag Farmaceutica S.A. 100% Argentina\n\n56. Janssen de Mexico S. de R.L. de 100% Mexico C.V. Janssen Inc. 100% Canada Janssen Infectious 100% Belgium Diseases-Diagnostics BVBA Janssen Korea Ltd. 100% Korea (South) Janssen Pharmaceutica NV 100% Belgium Janssen Pharmaceutical 100% Ireland Janssen Pharmaceutical Holdings 100% Ireland Janssen Pharmaceutical K.K. 100% Japan Janssen R&D Ireland 100% Ireland Janssen-Cilag 100% France Janssen-Cilag AB 100% Sweden Janssen-Cilag AG 100% Switzerland Janssen-Cilag B.V. 100% Netherlands Janssen-Cilag Farmaceutica Ltda. 100% Brazil Janssen-Cilag Farmaceutica, Lda. 100% Portugal Janssen-Cilag GmbH 100% Germany Janssen Cilag Limited 100% Thailand Janssen-Cilag Limited 100% United Kingdom Janssen-Cilag NV 100% Belgium Janssen-Cilag OY 100% Finland Janssen-Cilag Pharma GmbH 100% Austria Janssen-Cilag Pharmaceutical 100% Greece\n\n57. Johnson & Johnson 09/23/2015 10 Mergent, Inc. SUBSIDIARY NAME PERCENT OWNED COUNTRY S.A.C.I. Janssen-Cilag Pty Ltd 100% Australia Janssen-Cilag S.p.A. 100% Italy Janssen-Cilag, C.A. 100% Venezuela Janssen-Cilag, S.A. 100% Spain Janssen-Cilag, S.A. de C.V. 100% Mexico J-C Health Care Ltd. 100% Israel JJC Acquisition Company B.V. 100% Netherlands Johnson & Johnson (China) 100% China (Peoples Investment Ltd. Rep. Of) Johnson & Johnson (China) Ltd. 100% China (Peoples Rep. Of) Johnson & Johnson (Hong Kong) 100% Hong Kong Limited Johnson & Johnson (Ireland) 100% Ireland Limited Johnson & Johnson (New 100% New Zealand\n\n58. Zealand) Limited Johnson & Johnson 100% Philippines (Philippines), Inc. Johnson & Johnson 100% South Africa (Proprietary) Limited Johnson & Johnson (Thailand) 100% Thailand Ltd. Johnson & Johnson AB 100% Sweden Johnson & Johnson AG 100% Switzerland Johnson & Johnson Consumer 100% Thailand (Thailand) Limited Johnson & Johnson Consumer B.V. 100% Netherlands Johnson & Johnson Consumer 100% France Holdings France Johnson & Johnson Consumer 100% United Kingdom Services EAME Ltd. Johnson & Johnson de Argentina 100% Argentina S.A.C. e. I. Johnson & Johnson de Chile S.A. 100% Chile Johnson & Johnson de Colombia 100% Colombia S.A. Johnson & Johnson de Mexico, 100% Mexico S.A. de C.V. Johnson & Johnson de 100% Venezuela Venezuela, S.A.\n\n59. Johnson & Johnson del Ecuador 100% Ecuador S.A. Johnson & Johnson del Peru S.A. 100% Peru Johnson & Johnson do Brasil 100% Brazil Industria E Comercio de Produtos Para Saude Ltda. Johnson & Johnson European 100% Ireland Treasury Company Johnson & Johnson 09/23/2015 11 Mergent, Inc. SUBSIDIARY NAME PERCENT OWNED COUNTRY Johnson & Johnson Finance 100% United Kingdom Limited Johnson & Johnson Financial 100% Germany Services GmbH Johnson & Johnson Gesellschaft 100% Austria m.b.H. Johnson & Johnson GmbH 100% Germany Johnson & Johnson Group 100% Germany Holdings GmbH\n\n60. Johnson & Johnson Hellas 100% Greece Commercial and Industrial S.A. Johnson & Johnson Holding GmbH 100% Germany Johnson & Johnson Inc. 100% Canada Johnson & Johnson Industrial 100% Brazil Ltda. Johnson & Johnson 100% Ireland International Financial Services Company Johnson & Johnson K.K. 100% Japan Johnson & Johnson Kft. 100% Hungary Johnson & Johnson Korea 100% Korea (South) Selling & Distribution Limited Liability Company Johnson & Johnson Korea, Ltd. 100% Korea (South) Johnson & Johnson Limitada 100% Portugal Johnson & Johnson Limited 100% India Johnson & Johnson Limited 100% United Kingdom Johnson & Johnson LLC 100% Russia Johnson & Johnson Luxembourg 100% Luxembourg Finance Company Sarl Johnson & Johnson Management 100% United Kingdom Limited Johnson & Johnson Medical 100% China (Peoples (China) Ltd. Rep. Of)\n\n61. Johnson & Johnson Medical 100% South Africa (Pty) Limited Johnson & Johnson Medical 100% China (Peoples (Shanghai) Ltd. Rep. Of) Johnson & Johnson Medical 100% China (Peoples (Suzhou) Ltd. Rep. Of) Johnson & Johnson Medical B.V. 100% Netherlands Johnson & Johnson Medical GmbH 100% Germany Johnson & Johnson Medical 100% Korea (South) Korea Limited Johnson & Johnson Medical 100% United Kingdom Limited Johnson & Johnson Medical 100% Mexico Mexico, S.A. de C.V. Johnson & Johnson Medical NV 100% Belgium Johnson & Johnson Medical 100% Austria Johnson & Johnson 09/23/2015 12 Mergent, Inc. SUBSIDIARY NAME PERCENT OWNED COUNTRY Products GmbH\n\n62. Johnson & Johnson Medical Pty 100% Australia Ltd Johnson & Johnson Medical S.A. 100% Argentina Johnson & Johnson Medical 100% Italy S.p.A. Johnson & Johnson Medical, 100% Venezuela S.C.S. Johnson & Johnson Middle East 100% United Arab FZ-LLC Emirates Johnson & Johnson Pacific Pty. 100% Australia Limited Johnson & Johnson Poland Sp. z 100% Poland o.o. Johnson & Johnson Pte. Ltd. 100% Singapore Johnson & Johnson Pty. Limited 100% Australia Johnson & Johnson S.p.A. 100% Italy Johnson & Johnson SDN. BHD. 100% Malaysia Johnson & Johnson Sihhi 100% Turkey Malzeme Sanayi Ve Ticaret Limited Sirketi Johnson & Johnson Swiss 100% United Kingdom Finance Company Limited Johnson & Johnson Taiwan Ltd. 100% Taiwan Johnson & Johnson Vision Care 100% Ireland (Ireland)\n\n63. Johnson & Johnson, prodaja 100% Slovenia medicinskih in farmacevtskih izdelkov, d.o.o. Johnson & Johnson, S.A. 100% Spain Johnson & Johnson, S.A. de C.V. 100% Mexico Johnson & Johnson, s.r.o. 100% Czech Republic Latam International Investment 100% Ireland Company Latam Properties Holdings 100% Ireland LifeScan Scotland Limited 100% United Kingdom McNeil AB 100% Sweden McNeil GmbH & Co. oHG 100% Germany McNeil Healthcare (UK) Limited 100% United Kingdom McNeil Manufacturing Pty Ltd 100% Australia McNeil Products Limited 100% United Kingdom McNeil Sweden AB 100% Sweden Medos International Sarl 100% Switzerland Medos Sarl 100% Switzerland Mentor Medical Systems B.V. 100% Netherlands Mentor Medical Systems C.V. 100% Netherlands OBTECH Medical Sarl 100% Switzerland OMJ Ireland 100% Ireland OMJ PR Holdings 100% Ireland Omrix Biopharmaceuticals Ltd. 100% Israel\n\n64. Johnson & Johnson 09/23/2015 13 Mergent, Inc. SUBSIDIARY NAME PERCENT OWNED COUNTRY Ortho-Clinical Diagnostics 100% France Ortho-Clinical Diagnostics 100% United Kingdom Ortho-Clinical Diagnostics GmbH 100% Germany Ortho-Clinical Diagnostics K.K. 100% Japan Ortho-Clinical Diagnostics NV 100% Belgium P.T. Johnson & Johnson 100% Indonesia Indonesia Shanghai Elsker Mother & Baby 100% China (Peoples Co., Ltd Rep. Of) Shanghai Johnson & Johnson 100% China (Peoples Pharmaceuticals, Ltd. Rep. Of) Synthes (Canada) Ltd. 100% Canada Synthes (Shanghai) Medical Trading 100% China (Peoples Co., Ltd. Rep. Of) Synthes (Suzhou) Medical Co., Ltd. 100% China (Peoples Rep. Of) Synthes Australia Pty Ltd 100% Australia\n\n65. Synthes Colombia S.A.S. 100% Colombia Synthes Finanz AG 100% Switzerland SYNTHES GmbH 100% Germany Synthes GmbH 100% Switzerland Synthes Holding AG 100% Switzerland Synthes Industria e Comercio Ltda. 100% Brazil Synthes Limited 100% United Kingdom Synthes Lux Finance S.ar.l. 100% Luxembourg Synthes Lux Holding S.ar.l. 100% Luxembourg Synthes Luxembourg, S.ar.l. 100% Luxembourg Synthes Medical Private Limited 100% India Synthes Produktions GmbH 100% Switzerland Synthes Tuttlingen GmbH 100% Germany Synthes-Stratec S.A. 100% Spain Tasmanian Alkaloids Pty. Ltd. 100% Australia Tibotec-Virco Comm. VA 100% Belgium Turnbuckle Investment Company 100% Ireland Vania Expansion 100% France Xian-Janssen Pharmaceutical Ltd. 100% China (Peoples Rep. Of) Long Term Debt Dec. 28, 2014, $15,129,000,000 (including current portion of $7,000,000) comprised of:\n\n66. -- 01 -- $898,000,000 2.15% notes, due 2016. -- 02 -- $800,000,000 long-term debt, bearing interest at three month London Interbank Offered Rate (LIBOR) plus 0.07% FRN (effective interest rate was 0.31% at Dec. 28, 2014), due 2016. -- 03 -- $398,000,000 0.70% notes, due 2016. -- 04 -- $1,000,000,000 5.55% debentures, due 2017. Johnson & Johnson 09/23/2015 14 Mergent, Inc. -- 05 -- $697,000,000 1.125% notes, due 2017. -- 06 -- $898,000,000 5.15% debentures, due 2018. -- 07 -- $597,000,000 1.65% notes, due 2018. -- 08 -- $1,216,000,000 4.75% notes, due 2019.\n\n67. -- 09 -- $497,000,000 1.875% notes, due 2019. -- 10 -- $158,000,000 3% zero coupon convertible subordinated debentures, due 2020. -- 11 -- $543,000,000 2.95% debentures, due 2020. -- 12 -- $446,000,000 3.55% notes, due 2021. -- 13 -- $349,000,000 2.45% notes, due 2021. -- 14 -- $250,000,000 6.73% debentures, due 2023. -- 15 -- $812,000,000 3.375% notes, due 2023. -- 16 -- $772,000,000 5.50% notes, due 2024. -- 17 -- $297,000,000 6.95% notes, due 2029. -- 18 -- $500,000,000 4.95% debentures, due 2033. -- 19 -- $865,000,000 4.375% notes, due 2033. -- 20 -- $995,000,000 5.95% notes, due 2037.\n\n68. -- 21 -- $700,000,000 5.85% debentures, due 2038. -- 22 -- $539,000,000 4.50% debentures, due 2040. -- 23 -- $298,000,000 4.85% notes, due 2041. -- 24 -- $499,000,000 4.50% notes, due 2043. -- 25 -- $105,000,000 other long-term debt. Line of Credit: Co. has access to substantial sources of funds at several banks worldwide. In Sept. 2014, Co. secured a 364-day Credit Facility. Total credit available to Co. approximates $10,000,000,000, which expires on Sept. 17, 2015. Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate or LIBOR, plus applicable margins. For details see below. Expanded Long Term Debt CUSIP Issuer Name Issue Description Ticker\n\n69. Johnson & Johnson 09/23/2015 15 Mergent, Inc. CUSIP Issuer Name Issue Description Ticker 478160AB0 JOHNSON & JOHNSON NT JNJ 478160AA2 JOHNSON & JOHNSON NT JNJ 478160AC8 JOHNSON & JOHNSON NT JNJ 478160AD6 JOHNSON & JOHNSON NT JNJ 218525AA1 CORDIS CORPORATION SUB DEB JNJ 152342AB7 CENTOCOR INCORPORATED SUB DEB CONV JNJ 152342AA9 CENTOCOR INCORPORATED SUB NT CONV JNJ 4781609A0 JOHNSON & JOHNSON NT REG S JNJ 478160AE4 JOHNSON & JOHNSON NT JNJ 421969AA4 HEARTPORT INCORPORATED SUB NT CONV RULE 144A JNJ 421969AC0 HEARTPORT INCORPORATED SUB NT CONV JNJ 152342AE1 CENTOCOR INCORPORATED SUB DEB CONV JNJ 022615AD0 ALZA CORPORATION SUB DEB CONV JNJ\n\n70. 808905AB9 SCIOS INCORPORATED SUB NT CONV JNJ 808905AA1 SCIOS INCORPORATED SUB NT CONV RULE 144A JNJ 478160AK0 JOHNSON & JOHNSON DEB JNJ 022615AB4 ALZA CORPORATION LIQUID YIELD OPT NT JNJ (LYONS) 478160AP9 JOHNSON & JOHNSON GLOBAL NT JNJ 478160AM6 JOHNSON & JOHNSON GLOBAL DEB JNJ 022615AC2 ALZA CORPORATION SUB NT ZERO CPN CONV JNJ (LYON) 478160AQ7 JOHNSON & JOHNSON GLOBAL NT JNJ 478160AS3 JOHNSON & JOHNSON EUR$ GLOBAL NT JNJ 02261WAB5 ALZA CORPORATION SUB DEB ZERO CPN CONV JNJ 02261WAA7 ALZA CORPORATION SUB DEB ZERO CPN CONV JNJ RULE 144A 478160AF1 JOHNSON & JOHNSON DEB JNJ 478160AG9 JOHNSON & JOHNSON DEB JNJ 478160AR5 JOHNSON & JOHNSON GBP$ GLOBAL NT JNJ\n\n71. 478160AJ3 JOHNSON & JOHNSON DEB JNJ 478160AL8 JOHNSON & JOHNSON GLOBAL DEB JNJ 478160AN4 JOHNSON & JOHNSON GLOBAL NT JNJ CUSIP Coupon Maturity Active 478160AB0 8.87510/15/1990 No 478160AA2 9.12509/15/1992 No 478160AC8 8.508/15/1995 No 478160AD6 809/01/1998 No 218525AA1 12.2506/15/1999 No 152342AB7 6.7502/01/2001 No 152342AA9 7.2502/01/2001 No 4781609A0 607/19/2001 No 478160AE4 7.37506/29/2002 No 421969AA4 7.2505/01/2004 No 421969AC0 7.2505/01/2004 No 152342AE1 4.7502/15/2005 No 022615AD0 505/01/2006 No 808905AB9 5.508/15/2009 No 808905AA1 5.508/15/2009 No Johnson & Johnson\n\n72. 09/23/2015 16 Mergent, Inc. CUSIP Coupon Maturity Active 478160AK0 6.62509/01/2009 No 022615AB4 012/21/2010 No 478160AP9 5.1508/15/2012 No 478160AM6 3.805/15/2013 No 022615AC2 007/14/2014 No 478160AQ7 5.5508/15/2017 Yes 478160AS3 -11/06/2019 Yes 02261WAB5 007/28/2020 Yes 02261WAA7 007/28/2020 No 478160AF1 6.7311/15/2023 Yes 478160AG9 8.7211/01/2024 No 478160AR5 -11/06/2024 Yes 478160AJ3 6.9509/01/2029 Yes 478160AL8 4.9505/15/2033 Yes 478160AN4 5.9508/15/2037 Yes Capital Structure Abbreviation Description Structure Type Exchange Ticker Market Cap\n\n73. Com Com Common NYS JNJ 258,191,443,440 Business Segments Business Analysis Revenues Report Date 12/28/2014 12/29/2013 12/30/2012 01/01/2012 Currency USD USD USD USD Scale Millions Millions Millions Millions Consumer 14,496 14,697 14,447 14,883 Pharmaceutical 32,313 28,125 25,351 24,368 Medical Devices & Diagnostics 27,522 28,490 27,426 25,779 Total 74,331 71,312 67,224 65,030 Operating Income Report Date 01/02/2011 12/28/2014 12/29/2013 12/30/2012 Currency USD USD USD USD Scale Millions Millions Millions Millions Consumer 14,590 1,941 1,973 1,693 Pharmaceutical 22,396 11,696 9,178 6,075 Medical Devices & Diagnostics 24,601 7,953 5,261 7,187 Total 61,587 21,590 16,412 14,955 Report Date 01/01/2012 01/02/2011\n\n74. Currency USD USD Johnson & Johnson 09/23/2015 17 Mergent, Inc. Report Date 01/01/2012 01/02/2011 Currency USD USD Scale Millions Millions Consumer 2,096 2,342 Pharmaceutical 6,406 7,086 Medical Devices & Diagnostics 5,263 8,272 Total 13,765 17,700 Geographic Analysis Revenues Report Date 12/28/2014 Currency USD Scale Millions United States 34,782 Europe 18,947 Western Hemisphere excluding U.S. 7,160\n\n75. Asia-Pacific, Africa 13,442 Total 74,331 Report Date 12/29/2013 Currency USD Scale Millions United States 31,910 Europe 18,599 Western Hemisphere excluding U.S. 7,421 Asia-Pacific, Africa 13,382 Total 71,312 Johnson & Johnson 09/23/2015 18 Mergent, Inc. Report Date 12/30/2012 Currency USD Scale Millions United States 29,830 Europe 16,945 Western Hemisphere excluding U.S. 7,207 Asia-Pacific, Africa 13,242\n\n76. Total 67,224 Report Date 01/01/2012 Currency USD Scale Millions United States 28,908 Europe 17,129 Western Hemisphere excluding U.S. 6,418 Asia-Pacific, Africa 12,575 Total 65,030 Johnson & Johnson 09/23/2015 19 Mergent, Inc. Report Date 01/02/2011 Currency USD Scale Millions United States 29,450 Europe 15,510 Western Hemisphere excluding U.S. 5,550 Asia-Pacific, Africa 11,077 Total 61,587\n\n77. Johnson & Johnson (NYS: JNJ) Report: J&J had plan to block more FDA restrictions on Tylenol BioPharma Dive - 12:02PM, 23 September 2015 FDA Was Pressured By J&J Not to Address Tylenol Liver Damage Risk: Report AboutLawsuits.com - 11:11AM, 23 September 2015 U of Toronto to collaborate with Johnson & Johnson on health start-ups Technology Transfer Tactics - 11:10AM, 23 September 2015 Nike, Johnson & Johnson, Starbucks, And Others Join Pledge For 100% Renewable Electricity CleanTechnica - 9:52AM, 23 September 2015 Dishman gets licence from JJ to make TB drug raw material Money Control - 9:00AM, 23 September 2015 Risperdal Litigation Pioneer Stephen Sheller Featured in \"DocuSerial\" about Johnson & Johnson, \"America's Most Admired Lawbreaker\" by Steve Brill\n\n78. PR Newswire - 8:19AM, 23 September 2015 Dishman Pharma to make TB drug exclusively for JJ Money Control - 3:21AM, 23 September 2015 Fortune 500 listed companies pledge to use 100% renewable electricity Blue and Green Tomorrow - 11:10PM, 22 September 2015 Johnson & Johnson: A Gold Standard Dividend Stock Seeking Alpha - 3:00PM, 22 September 2015 J&J faces Tylenol lobbying allegations in first case to go to trial over med FiercePharma - 11:03AM, 22 September 2015 Alex Gorsky Title : Chairman Tenure : 27 Age : 55 Total Compensation : $61,989,306 %Change : 2.67 Education : - Dominic J. Caruso Title : Vice President Johnson & Johnson (NYS: JNJ)\n\n79. Key Officers Tenure : 16 Age : 57 Total Compensation : $10,349,033 %Change : 0.26 Education : - Peter M. Fasolo Title : Vice President Tenure : 5 Age : 52 Total Compensation : $3,621,281 %Change : - Education : - Michael H. Ullmann Title : Vice President Tenure : 26 Age : 57 Total Compensation : $5,960,691 %Change : 0.37 Education : - Paulus Stoffels Title : Chief Scientific Officer Tenure : 13 Age : 53 Total Compensation : $18,339,317 %Change : 1.34\n\n80. Education : - Stephen J. Cosgrove Title : Chief Accounting Officer Tenure : - Age : - Total Compensation : $- %Change : - Education : - Sandra E. Peterson Title : Group Worldwide Chair Tenure : 3 Age : 56 Total Compensation : $7,086,606 %Change : 0.26 Education : - Douglas K. Chia Title : Secretary Tenure : 9 Age : - Total Compensation : $- %Change : - Education : - Ronald A. Kapusta Title : Division Officer\n\n81. Tenure : 23 Age : 56 Total Compensation : $- %Change : - Education : - Lacey P. Elberg Title : Assistant Secretary Tenure : - Age : - Total Compensation : $- %Change : - Education : - Total Institutions: 2,777 2,062 Total Shares Held: 2,117,236,303 % of Shares Held: 64.40% Changes In: New/Increased vs Old/Decreased Positions: -259 Amount of Shares Held: -167,217,071 % of shares held change: -77.03% 64.40% Held By Institutions -77.03% Shares Held Change\n\n82. New Positions Increased Positions Closed Positions Decreased Positions Unchanged Positions Institutions: 0 Institutions: 1,103 Institutions: 60 Institutions: 1,302 Institutions: 372 Shares: 0 Shares: 911,498,337 Shares: 9,450,411 Shares: 1,069,264,997 Shares: 136,472,969 % Change: 0.00% % Change: 88.02% % Change: 30.16% % Change: 86.82% % Change: 51.89% Top 25 Institution Holders Johnson & Johnson (NYS: JNJ) Institution Name New/Closed Position Filing Date Total Shares Total\n\n83. Values Change in Shares VANGUARD GROUP INC - 6/30/2015 169,928,015 16,561,185 1,032,227 STATE STREET CORP - 6/30/2015 150,057,349 14,624,585 (5,247,524) BLACKROCK INSTITUTIONAL TRUST COMPANY - 6/30/2015 74,883,668 7,298,162 (1,705,895) FMR LLC - 6/30/2015 52,334,199 5,100,491 (9,100,250) BANK OF NEW YORK MELLON CORP - 6/30/2015 43,498,631 4,239,377 (54,688) WELLINGTON MANAGEMENT CO LLP - 6/30/2015 38,634,914 3,765,359 (239,427)\n\n84. NORTHERN TRUST CORP - 6/30/2015 38,281,191 3,730,884 339,369 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO - 6/30/2015 37,878,592 3,691,648 0 BLACKROCK FUND ADVISORS - 6/30/2015 37,510,345 3,655,758 2,427,084 J P MORGAN CHASE & CO - 6/30/2015 34,415,048 3,354,091 (10,609,645) MASSACHUSETTS FINANCIAL SERVICES CO /MA/\n\n85. - 6/30/2015 30,006,715 2,924,454 (828,631) BLACKROCK GROUP LTD - 6/30/2015 25,020,880 2,438,535 1,099,430 BANK OF AMERICA CORP /DE/ - 6/30/2015 24,256,214 2,364,010 (611,519) GEODE CAPITAL MANAGEMENT LLC - 6/30/2015 22,679,702 2,206,159 14,733 CAPITAL WORLD INVESTORS - 6/30/2015 21,950,000 2,139,247 (1,895,000) AMERIPRISE FINANCIAL INC\n\n86. - 6/30/2015 19,881,466 1,937,322 1,488,439 PRICE T ROWE ASSOCIATES INC /MD/ - 6/30/2015 18,936,971 1,845,597 (20,412) WELLS FARGO & CO/MN - 6/30/2015 17,922,831 1,746,760 250,177 MORGAN STANLEY - 6/30/2015 17,264,545 1,682,603 760,241 BARROW HANLEY MEWHINNEY & STRAUSS INC - 6/30/2015 15,632,757 1,523,568 (43,605) FRANKLIN RESOURCES INC - 6/30/2015 15,181,005 1,479,540 361,602\n\n87. GOLDMAN SACHS GROUP INC/ - 6/30/2015 13,239,653 1,290,337 1,700,452 JOHNSON ROBERT WOOD FOUNDATION - 6/30/2015 13,000,000 1,266,980 0 - 6/30/2015 12,932,504 1,260,402 (1,267,994) Institution Name New/Closed Position Filing Date Total Shares Total\n\n88. Values Change in Shares TIAA CREF INVESTMENT MANAGEMENT LLC DEUTSCHE BANK AG - 6/30/2015 12,931,691 1,260,315 (2,373,836) Johnson & Johnson (NYS: JNJ) Results are the first 25 filings from the last 90 days. For additional filings, please use Edgar Search Click here for Edgar Search JOHNSON & JOHNSON Results - select format to view filing. Select to add the filing to the Batch Printing list to download/print multiple filings at once Filing Type Filing Date Filing Size Accession Number View\n\n89. Documents Select Section (View In Text Only) 4 09/10/2015 4kb 0001225208-15- 4 09/10/2015 4kb 0001225208-15- 4 09/10/2015 4kb 0001225208-15- 4 09/10/2015 4kb 0001225208-15- SC 13G 08/28/2015 69kb 0000904454-15-000543 Entire Filing 4 08/12/2015 9kb 0000904454-15- 4 08/10/2015 4kb 0001225208-15- 10-Q 07/31/2015 4962kb 0000200406-15-000044 10-Q 2Q 8-K 07/14/2015 2058kb 0000200406-15-000042 8- SC 13G 07/07/2015 72kb 0000904454-15-000449 Entire Filing 3 07/06/2015 5kb 0000904454-15- 11-K 06/25/2015 385kb 0000200406-15-000039 11- 11-K 06/25/2015 374kb 0000200406-15-000038 11- 11-K 06/25/2015 400kb 0000200406-15-000037 11- Business Summary Johnson & Johnson is a holding company. Through its subsidiaries, Co. is organized into three\n\n90. segments. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopaedic, surgical care, specialty surgery, cardiovascular care, diagnostics, diabetes care, and vision care markets, which are distributed to wholesalers, hospitals and retailers. Pricing Summary Time Period: 1 week Yesterday 5 Days 30 Days Close 93.24 93.39 92.82 Volume 10,618,620.00 14,211,147.00 25,633,357.00 Key Executives Alex Gorsky Age Salary Chairman,Chief Executive Officer\n\n91. 55 1,500,000 Dominic Caruso Age Salary Vice President,Chief Financial Officer 57 878,115 Peter Fasolo Age Salary Vice President 52 534,769 Michael Ullmann Age Salary Vice President,General Counsel 57 591,346 Paulus Stoffels Age Salary Chief Scientific Officer 53 1,075,423\n\n92. Key Financials (In USD as of 06/28/2015) Income Statement Revenue 71,882m Net Income 16,106m EPS from Continuing Operations 5.69 EPS - Net Income - Diluted 5.69 Revenue per Share 25.93 Balance Sheet Total Assets 132,036m Total Liabilities 60,905m Shareholders' Equity 71,131m Total Assets per Share 47.68 Net Assets per Share 25.69 Cash Flows Cash from Operations 17,091m Cash from Investing -7,530m Cash from Financing -12,065m Capital Expenditures 3,555m Cash Flow per Share 6.08 Johnson & Johnson (NYS: JNJ)\n\n93. Yesterday 5 Days 30 Days 52 Week High/Low : 109.07 - 90.73 % Price Change (100 Days) : -4.36 200-Day Moving Avg. : 98.98 Company News 12:02PM, 23 September 2015 - Report: J&J had plan to block more FDA restrictions on Tylenol - BioPharma Dive 11:11AM, 23 September 2015 - FDA Was Pressured By J&J Not to Address Tylenol Liver Damage Risk: Report - AboutLawsuits.com 11:10AM, 23 September 2015 - U of Toronto to\n\n94. collaborate with Johnson & Johnson on health start- ups - Technology Transfer Tactics 9:52AM, 23 September 2015 - Nike, Johnson & Johnson, Starbucks, And Others Join Pledge For 100% Renewable Electricity - CleanTechnica 9:00AM, 23 September 2015 - Dishman gets licence from JJ to make TB drug raw material - Money Control 8:19AM, 23 September 2015 - Risperdal Litigation Pioneer Stephen Sheller Featured in \"DocuSerial\" about Johnson & Johnson, \"America's Most Admired Lawbreaker\" by Steve Brill - PR Newswire 3:21AM, 23 September 2015 - Dishman Pharma to make TB drug exclusively for JJ - Money Control 11:10PM, 22 September 2015 - Fortune 500 listed companies pledge to use 100% renewable electricity - Blue and Green Tomorrow 3:00PM, 22 September 2015 - Johnson & Johnson: A Gold Standard Dividend Stock - Seeking Alpha 11:03AM, 22 September 2015 - J&J faces Tylenol lobbying allegations in first case to go to trial over med - FiercePharma Corporate Events\n\n95. Earnings Announcement Data - October 13 2015 Conference Call Announcements - October 13 2015 Conference Call Announcements - July 14 2015 Earnings Announcement Data - July 14 2015 Earnings Announcement Data - April 14 2015 Earnings Announcement Data - April 14 2015 Conference Call Announcements - April 14 2015 Johnson & Johnson (NYS: JNJ) Exchange rate used is that of the Year End reported date As Reported Annual Balance Sheet Report Date 12/28/2014 12/29/2013 1 12/30/2012 01/01/2012 01/02/2011 Currency USD USD USD USD USD Audit Status Not Qualified Not\n\n96. Qualified Not Qualified Not Qualified Not Qualified Consolidated Yes Yes Yes Yes Yes Scale Millions Millions Millions Millions Millions Cash & cash equivalents 14,523 20,927 14,911 24,542 19,355 Marketable securities 18,566 8,279 6,178 7,719 8,303 Accounts receivable, trade, gross 11,260 12,046 11,775 10,942 10,114 Less: allowance for doubtful accounts 275 333 466 361 340 Accounts receivable, trade,\n\n97. net 10,985 11,713 11,309 10,581 9,774 Raw materials & supplies 1,214 1,224 1,416 1,206 1,073 Goods in process 2,461 2,612 2,262 1,637 1,460 Finished goods 4,509 4,042 3,817 3,442 2,845 Inventories 8,184 7,878 7,495 6,285 5,378 Deferred taxes on income 3,567 3,607 3,139 2,556 2,224 Prepaid expenses & other receivables 3,486 4,003 3,084 2,633 2,273 Total current assets 59,311 56,407 46,116 54,316 47,307 Land & land improvements 833 885 793 754 738 Buildings & building equipment 10,046 10,423 10,046 9,389 9,079 Machinery & equipment 22,206 22,527 21,075 19,182 18,032 Construction in progress 3,600 3,298 2,740 2,504 2,577 Property, plant & equipment, cost\n\n98. 36,685 37,133 34,654 31,829 30,426 Less: accumulated depreciation 20,559 20,423 18,557 17,090 15,873 Property, plant & equipment, net 16,126 16,710 16,097 14,739 14,553 Report Date 12/28/2014 12/29/2013 1 12/30/2012 01/01/2012 01/02/2011 Currency USD USD USD USD USD Audit Status Not Qualified Not Qualified Not\n\n99. Qualified Not Qualified Not Qualified Consolidated Yes Yes Yes Yes Yes Scale Millions Millions Millions Millions Millions Intangible assets, net 27,222 27,947 28,752 18,138 16,716 Goodwill, net 21,832 22,798 22,424 16,138 15,294 Deferred taxes on income 3,396 3,872 4,541 6,540 5,096 Other assets 3,232 4,949 3,417 3,773 3,942 Total assets 131,119 132,683 121,347 113,644 102,908 Loans & notes payable 3,638 4,852 4,676 6,658 7,617 Accounts payable 7,633 6,266 5,831 5,725 5,623 Accrued liabilities 6,553 7,685 7,299 4,608 4,100 Accrued rebates, returns & promotions 4,010 3,308 2,969 2,637 2,512 Accrued compensation & employee related obligations\n\n100. 2,751 2,794 2,423 2,329 2,642 Accrued taxes on income 500 770 1,064 854 578 Total current liabilities 25,085 25,675 24,262 22,811 23,072 Zero coupon convertible subordinated debentures 158 179 205 199 194 Debentures 4,430 8,792 4,929 5,527 5,027 Notes 9,636 4,429 6,556 6,477 3,872 FRN 800 1,550 1,250 1,250 - Other long-term debt 105 147 61 132 76 Total long-term debt 15,129 15,097 13,001 13,585 9,169 Less: current portion 7 1,769 1,512 616 13 Long-term debt 15,122 13,328 11,489 12,969 9,156 Deferred taxes on income 3,154 3,989 3,136 1,800 1,447 Pension benefits 4,547 2,950 4,488 3,937 2,175 Postretirement benefits 3,161 2,655 2,789 2,843 2,359 Postemployment benefits 2,062 1,872 1,452 1,129 1,379 Deferred compensation 599 693 747 863 820 Total employee related obligations before current benefits payable\n\n101. 10,369 8,170 9,476 8,772 6,733 Less: current benefits payable (397) (386) (394) (419) (646) Employee related obligations 9,972 7,784 9,082 8,353 6,087 Other liabilities 8,034 7,854 8,552 10,631 6,567 Total liabilities 61,367 58,630 56,521 56,564 46,329 Common stock 3,120 3,120 3,120 3,120 3,120 Report Date 12/28/2014 12/29/2013 1 12/30/2012 01/01/2012 01/02/2011 Currency USD USD USD USD USD Audit Status Not Qualified Not Qualified Not\n\n102. Qualified Not Qualified Not Qualified Consolidated Yes Yes Yes Yes Yes Scale Millions Millions Millions Millions Millions Foreign currency translations (4,803) (202) (296) (1,526) (969) Gains (losses) on securities 257 106 195 448 24 Employee benefit plans (6,317) (3,009) (5,717) (4,386) (2,686) Gains (losses) on derivatives & hedges 141 245 8 (168) 100 Accumulated other comprehensive income (loss) (10,722) (2,860) (5,810) (5,632) (3,531) Retained earnings (accumulated deficit)\n\n103. 97,245 89,493 85,992 81,251 77,773 Total equity before treasury stock 89,643 89,753 83,302 78,739 77,362 Less: common stock held in treasury, at cost 19,891 15,700 18,476 21,659 20,783 Total shareholders' equity (deficit) 69,752 74,053 64,826 57,080 56,579 1 Reclassified to conform with 2014 presentation Johnson & Johnson (NYS: JNJ) Annual Reports\n\n104. Note: Company Reports selections are in PDF format. In order to view PDF selections, you must have Adobe Acrobat Reader Year File Size Language 2014-12-28 10K or Int'l Equivalent 334K English 2013-12-31 Annual Report 3233K English 2013-12-29 10K or Int'l Equivalent 332K English 2012-12-30 10K or Int'l Equivalent 1196K English 2012-01-01 Annual Report 4770K English 2011-01-02 Annual Report 3161K English 2011-01-02 10K or Int'l Equivalent 50K English 2010-01-03 Annual Report 2465K English 2010-01-03 10K or Int'l Equivalent 66K English 2009-01-03 Annual Report 2465K English 2008-12-28 Annual Report 4226K English 2007-12-31 Annual Report 3531K English 2007-12-30 10K or Int'l Equivalent 479K English 2006-12-31 Annual Report 3647K English 2006-01-01 Annual Report 2193K English 2005-01-02 Annual Report 1828K English 2003-12-28 Annual Report 3381K English 2002-12-29 Annual Report 2301K English 2001-12-30 Annual Report 2089K English 2000-12-31 Annual Report 5491K English"
    }
}